The Longevity Peptide
Epitalon (Epithalamion / Ala-Glu-Asp-Gly)
Epithalon is a synthetic tetrapeptide (4 amino acids: Ala-Glu-Asp-Gly) based on the natural peptide Epithalamin, which is produced by the pineal gland. Developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, Epithalon is the most studied peptide in the field of bioregulation and longevity research, with over 40 years of research behind it.
Epithalon's primary mechanism is the activation of telomerase, the enzyme responsible for maintaining telomere length. By preventing telomere shortening, it may slow cellular aging and extend the replicative lifespan of cells.
Activates telomerase, the enzyme that adds protective telomere sequences to the ends of chromosomes, preventing the shortening that occurs with each cell division.
Regulates melatonin production in the pineal gland, restoring circadian rhythm function that typically declines with age.
Modulates expression of genes associated with aging, inflammation, and cellular stress responses.
Demonstrates antioxidant properties by reducing lipid peroxidation and enhancing the activity of endogenous antioxidant enzymes.
Primary benefit is activation of telomerase, which maintains telomere length and may slow the cellular aging process at the chromosomal level.
By restoring pineal gland function and melatonin production, Epithalon may help normalize sleep patterns that deteriorate with age.
Research shows reduction in oxidative stress markers and enhanced activity of the body's natural antioxidant defense systems.
Studies suggest Epithalon may help restore age-related immune decline by supporting thymus function and T-cell activity.
Epithalon induced telomerase activity in human somatic cells, increasing telomere length and extending the replicative lifespan of cultured fibroblasts by over 40%.
Long-term studies in rodent models showed Epithalon administration increased mean lifespan by 13-24% compared to controls, with improved physiological markers.
A 15-year observational study of elderly patients receiving Epithalamion showed 28% reduction in mortality and improved functional capacity compared to untreated controls.
Epithalon has been researched for over 40 years, primarily in Russian studies. It has demonstrated a very favorable safety profile with no significant adverse effects reported in clinical or preclinical studies. Its tetrapeptide structure is rapidly broken down into naturally occurring amino acids.
Research Status
Epithalon has over 40 years of research, primarily from the St. Petersburg Institute of Bioregulation and Gerontology. While the body of evidence is substantial, the majority comes from Russian research institutions. Independent Western replication of key findings is ongoing.
Regulatory Note
Epithalon is not FDA-approved. It is classified as a research compound in the US and is available through compounding pharmacies with a physician prescription in some jurisdictions.